Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
HIT-HARD trial of short-course high-dose versus conventional beta-lactam antibiotics in critically ill adults
2024-514730-21-00Phase 3Authorised
- Sponsor
- Ghent University Hospital
- Start
- Jul 2025
- Modality
- Small Molecules, Irreversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 2
01
Overview
Phase 3, randomised, open-label trial of piperacillin + tazobactam, ceftriaxone, meropenem, cefotaxime and cefuroxime in bacterial disease, community-acquired pneumonia (CAP), hospital-acquired pneumonia (HAP) and 3 more (2 arms), sponsored by Ghent University Hospital. Primary endpoint: All-cause mortality within 90 days after enrolment. Planned start Jul 2025; status: authorised.
02
Drugs
piperacillin + tazobactamceftriaxonemeropenemcefotaximecefuroxime
03
Conditions
bacterial diseasecommunity-acquired pneumonia (CAP)hospital-acquired pneumonia (HAP)ventilator-associated pneumonia (VAP)Intra-abdominal infection (IAI)
Beyond the preview
Go deeper on 2024-514730-21-00.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on 2024-514730-21-00.